Glutamate transport by the excitatory amino acid transporters (EAATs) is coupled to the co-transport of 3 Na ؉ , 1 H ؉ , and the counter-transport of 1 K ؉ ion. In addition to coupled ion fluxes, glutamate and Na ؉ binding to the transporter activates a thermodynamically uncoupled anion conductance through the transporter. In this study, we have distinguished between these two conductance states of the EAAT-1 transporter using a [2-(trimethylammonium)ethyl]methanethiosulfonatemodified V452C mutant transporter. Glutamate binds to the modified mutant transporter and activates the uncoupled anion conductance but is not transported. The selective alteration of the transport function without altering the anion channel function of the V452C mutant transporter suggests that the two functions are generated by distinct conformational states of the transporter.
Glutamate is the predominant excitatory neurotransmitter in the mammalian central nervous system, and the role of the excitatory amino acid transporters (EAATs) 1 is to regulate synaptic glutamate concentrations to maintain dynamic signaling between the presynaptic and postsynaptic membranes and also to prevent a build-up of toxic levels of glutamate. The energy used to drive the uphill transport of glutamate into the cell against a significant concentration gradient is derived from the coupling of transport to the co-transport of 3 Na ϩ and 1 H ϩ and the counter-transport of 1 K ϩ for each glutamate molecule (1, 2) . In addition to these coupled ion fluxes, glutamate bound to the transporter activates a thermodynamically uncoupled anion conductance through the transporter (3) (4) (5) .
Five different glutamate transporters have been identified, and their amino acid sequences were determined from the cDNA sequences. The human glutamate transporters are termed EAAT-1 to EAAT-5 (3, 6, 7) , whereas the rat homologs of EAAT-1 and EAAT-2 are termed glutamate/aspartate transporter-1 (8) and glutamate transporter-1 (9) and the rabbit homolog of EAAT-3 is termed excitatory amino-acid carrier-1 (10) . The five different transporter subtypes show a high degree of similarity and are likely to form similar structures in the membrane. A number of models for the membrane topology of glutamate transporters have been proposed. Initial predictions of the topology from hydrophobicity analysis of the amino acid sequence lead to three different models with 8, 10, and 12 transmembrane domains (8 -10) , but more direct structural information has been obtained from method studies of substituted cysteine accessibility (11, 12) . The models proposed from these studies both predict six ␣-helical transmembrane domains in the amino-terminal portion of the protein followed by a series of reentrant loops and membrane-associated structures followed by a final ␣-helical transmembrane domain and an intracellular carboxyl-terminal domain.
The reentrant loop and membrane-associated structures are highly conserved in their amino acid sequences, and from mutagenesis studies, it has been proposed that this region forms the pore structure through which glutamate and the various co-transported and counter-transported ions pass. However, it remains to be demonstrated whether any of these residues also interact with anions, which raises the question as to whether the same region of the transporter that mediates the transport process is also responsible for allowing the uncoupled anion conductance. In a recent study (13) , we demonstrated that Zn 2ϩ ions selectively inhibit the anion conductance with no significant effect on the transport characteristics of the glutamate transporter EAAT-4, which suggests that the transport and anion conductances are mediated by distinct conformational states of the transporter. The Zn 2ϩ binding site was found to be in the large second extracellular loop, which is in a region that is distinct from the reentrant loops and transmembrane domains that interact with glutamate and the co-transported and counter-transported cations.
The aim of this study is to further investigate the conformational states responsible for the transport and anion channel functions of the transporter. We have attempted to identify amino acid residues, which when changed to cysteine and modified with the methanethiosulfonate (MTS) class of compounds (14, 15) , differentially alter the transport and anion channel properties of the transporter. To achieve this result, amino acid residues, which are accessible to MTS reagents and in close proximity to the pore region but do not directly interact with either glutamate or the co-transported and counter-transported cations, were targeted. Seal et al., (12) identified a number of amino acid residues in a membrane-associated linker region that are accessible to MTS reagents, which appear to satisfy these criteria. In this study, we report [2-(trimethylammonium)ethyl]methanethiosulfonate (MTSET) modification of the EAAT-1 mutant V452C blocks glutamate transport but does not interfere with glutamate binding to the transporter and activation of the uncoupled anion conductance. The selective disruption of transport while maintaining the anion channel function of EAAT-1 suggests that different conformational states of the transporter mediate the two functions.
MATERIALS AND METHODS
Chemicals-DL-Threo-␤-benzyloxyaspartate (TBOA) was obtained from Tocris (Bristol, UK), and MTS derivatives were obtained from Toronto Research Chemicals (Toronto, Ontario, Canada). All other chemicals were obtained from Sigma unless otherwise stated.
Site-directed Mutagenesis-EAAT-1 subcloned into the plasmid oocyte transcription vector (pOTV) was kindly supplied by Susan Amara (The Vollum Institute, Portland, OR). A cysteine-less EAAT-1 (CLE1) was engineered by making conservative substitutions of the three native cysteine residues in EAAT-1 (C186A, C252A, and C375A) using the QuikChange TM site-directed mutagenesis kit and recommended protocol (Stratagene). Valine 452 was also mutated to a cysteine residue, V452C, using the same protocol. Both CLE1 and V452C were sequenced on both strands by dye terminator cycle sequencing (ABI PRISM, PerkinElmer Life Sciences) at the Sydney University Prince Alfred Macromolecular Analysis Center.
Transporter Expression in Xenopus laevis Oocytes and Electrophysiological Recordings-The CLE1 and V452C transporter cDNAs were linearized with BamHI and cRNA transcribed with T7 RNA polymerase and capped with 5Ј-7-methylguanosine using the mMessage mMachine kit (Ambion, Inc., TX). Oocytes were harvested from X. laevis as described previously (16) , and 50 nl of cRNA was injected into defoliculated stage V oocytes and incubated in standard frog Ringer's solution called ND96 (96 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , 1.8 mM CaCl 2 , 5 mM HEPES, pH 7.55) supplemented with 2.5 mM sodium pyruvate, 0.5 mM theophylline, 50 g/ml gentamicin. Current recordings were made 2-5 days later using the two-electrode voltage clamp technique with a Geneclamp 500 amplifier (Axon instruments, Foster City, CA) interfaced with a MacLab 2e chart recorder (ADI Instruments, Sydney, Australia) using the Chart software and a Digidata 1200 (Axon Instruments), which is controlled by an IBM-compatible computer installed with pClamp software, version 7.0 (Axon Instruments).
The current-voltage relationships for substrate-elicited conductances were determined by subtraction of steady-state current measurements in the absence of substrate obtained during 200-ms voltage pulses from Ϫ30 mV to potentials between Ϫ100 and ϩ40 mV in 10 mV steps from corresponding current measurements in the presence of substrate. Current voltage measurements were normalized to the current generated by L-glutamate at Ϫ100 mV unless otherwise stated. In recordings in which the extracellular Cl Ϫ concentration was altered, equimolar substitutions were made with bromide (Br Ϫ ), iodide (I Ϫ ), or nitrate (N O 3 . ), and recordings were made with the bath grounded via a 3 M KCl/agar bridge connected to a 3 M KCl reservoir to minimize offset potentials. To measure reverse transport conductances, ND96 buffer was replaced with a high K ϩ buffer (46 mM NaCl, 50 mM KCl), and steady-state currents measured in the presence of 300 M TBOA during 200-ms voltage pulses from Ϫ30 mV to potentials between Ϫ100 and ϩ40 mV in 10 mV steps were subtracted from corresponding current measurements in high K ϩ buffer alone.
Radiotracer Flux Experiments-The uptake of L-[
3 H]glutamate (Amersham Biosciences) was measured in oocytes expressing CLE1, V452C, and uninjected oocytes by placing five oocytes in ND96 buffer containing 10 M L-[ 3 H]glutamate. MTSET-treated cells were incubated in 1 mM MTSET for 5 min and washed three times in ND96 at room temperature before uptake was performed. After 5 min, L-[ 3 H]glutamate uptake was terminated by three rapid washes in ice-cold ND96 buffer followed by lysis in 50 mM NaOH and scintillation counting. 3 H]Aspartate-loaded cells were incubated in the presence or absence of 1 mM MTSET for 5 min at room temperature and washed three times in buffer before release was initiated. Single oocytes were placed in 500 l of high K ϩ buffer (46 mM NaCl, 50 mM KCl) for 90 s, and 400 l of the external solution was then removed for scintillation counting and measurement of the extent of reverse transport. Background rates of release were measured in the presence of 1 mM TBOA. Oocytes were also removed, and the level of radioactivity was measured to confirm the extent of loading of 
RESULTS
The application of MTS derivatives to the wild-type EAAT-1 transporter does not alter its transport activity (19) . However, to ensure that further mutations do not expose a previously unreactive cysteine residue, a cysteine-less transporter was constructed. Conservative substitutions for the three endogenous cysteine residues (C186A, C252A, and C375A) resulted in a transporter termed CLE1. The application of L-glutamate or D-aspartate to oocytes expressing CLE1 elicits a conductance that is qualitatively similar to wild type in terms of current amplitude, rectification, and apparent substrate affinity (Fig.  1, A and C) . The application of 1 mM MTSET for 5 min caused no change in the L-glutamate-elicited or D-aspartate-elicited conductances (Fig. 1, A and C) .
The application of 100 M L-glutamate to oocytes expressing CLE1 or the V452C mutant generates similar conductances, which suggests that the cysteine mutation does not alter the structure or function of the transporter. The application of 1 mM MTSET does not affect the L-glutamate-activated conductance of CLE1 but does cause significant changes in the Lglutamate-activated conductance of the V452C mutant (Fig.  1B) . The amplitude of the current is decreased at negative potentials, and the reversal potential of the current is shifted 40 mV to more negative membrane potentials to Ϫ18.7 Ϯ 0.9 mV (n ϭ 6, p Ͻ 0.0001). Similar reductions in current amplitude and reversal potential measurements are also observed for D-aspartate-activated conductances (Fig. 1D ). Despite these differences, the EC 50 for the L-glutamate-activated conductances of the V452C mutant were not significantly different before and after treatment with MTSET or compared with the CLE1 transporter (Fig. 2) and the wild-type transporter (4, 20 -22) .
In wild-type EAAT-1, the glutamate-activated conductance is composed of an inwardly rectifying glutamate transport conductance and an uncoupled chloride conductance (4, 22) . In Xenopus laevis oocytes, the reversal potential for chloride ions is ϳϪ20 mV (3, 4, 23) , which is similar to the reversal potential observed for the V452C mutant after MTSET treatment (Ϫ18.7 Ϯ 0.9 mV). Thus, the effect of MTSET may be to selectively reduce the transport component of the conductance with chloride contributing a greater proportion of the current, resulting in the current reversing the direction closer to the reversal potential for chloride ions. To confirm this hypothesis, L-[ 3 H]glutamate uptake by oocytes expressing CLE1 and the V452C mutant with and without MTSET treatment was measured. Under control conditions with no MTSET treatment, the rates of L-[
3 H]glutamate uptake by oocytes expressing CLE1 and V452C-expressing oocytes are similar (Fig. 3) . After incubation of the oocytes with 1 mM MTSET, the rate of L-[
3 H]glutamate uptake by oocytes expressing CLE1 is unaffected, whereas the rate of uptake by oocytes expressing the V452C mutant is reduced to background levels (Fig. 3) . These results confirm that the rate of glutamate transport is unaffected by the V452C mutation and that application of MTSET to the V452C mutant transporter selectively inhibits the transport component of the glutamate-activated conductance.
The uncoupled anion conductance of the glutamate transporter family displays a chaotropic selectivity sequence in which some anions are more permeant than others (4, 5, 22) . With the more permeant anions in the extracellular solution, the substrate-induced currents are larger in amplitude and the reversal potential of these currents shifts to more hyperpolarized potentials as the proportion of the current being carried by the anions increases. When extracellular Cl Ϫ is substituted with either bromide (Br Ϫ ), iodide (I Ϫ ), or nitrate (NO 3 . ), the amplitude and reversal potential of the glutamate-activated currents of CLE1 and V452C (Fig. 4) are similar to that previously described for wild-type EAAT-1 (4, 22) . MTSET treatment does not affect the amplitudes or reversal potentials of the glutamate-activated conductances of CLE1 but does cause significant changes in the V452C mutant (Fig. 4) . MTSET treatment of V452C transporters increases the amplitude of the anion conductance and shifts the reversal potential to more hyperpolarized potentials. These results confirm that the application of glutamate to the mutant transporter after MTSET treatment still activates an anion conductance, but they also confirm that the nature of the anion conductance has not been altered.
The results presented thus far suggest that MTSET modification of the V452C mutant EAAT-1 does not affect glutamate binding and activation of the anion conductance but does inhibit glutamate transport. We have also investigated whether reverse transport and the reverse transport-activated chloride conductance (5) are similarly affected. To isolate reverse transport and reverse transport-activated chloride conductances, it was necessary to use the glutamate transport blocker TBOA (17) . TBOA is a non-transportable competitive inhibitor of glutamate transport that binds to the extracellular-facing glutamate binding site. However, before using TBOA to characterize reverse transport, we investigated its effect on forward transport under standard ionic conditions to confirm that it still binds to the mutant transporter. After MTSET treatment, increasing doses of TBOA caused a progressive reduction in the glutamate-activated conductance with an IC 50 of 43 M for CLE1 and 181 M for the V452C transporter (n ϭ 2, data not shown). Thus, although glutamate binding to either CLE1 or V452C is unaffected by MTSET treatment (see above), the affinity of TBOA for the MTSET-modified mutant is reduced. I(buffer) ). The data represented are normalized to the current elicited by 100 M L-glutamate at Ϫ100 mV and represent the mean currents Ϯ S.E. from five or more cells. After MTSET treatment of the V452C mutant transporter, the reversal potential of the L-glutamate-activated conductance shifted from ϩ19.3 Ϯ 1.7 mV to Ϫ18 Ϯ 0.9 mV (n ϭ 6). Similarly, D-aspartate-activated conductances were shifted from Ϫ1.3 Ϯ 1.6 mV to Ϫ18 Ϯ 0.9 mV (n ϭ 6). The Student's t test showed that these reversal potential shifts were significant (p Ͻ 0.0001).
Nonetheless, high doses of TBOA used in the following experiment still block a large proportion of the conductance elicited by 30 M L-glutamate.
Under conditions of elevated extracellular K ϩ and reduced extracellular Na ϩ , glutamate transporters may function in reverse (1, 24) . In X. laevis oocytes, this procedure may lead to the activation of a variety of conductances, but with the use of TBOA, it is possible to isolate the conductance changes that are specific to reverse operation of glutamate transporters. Under conditions of elevated extracellular K ϩ (50 mM) and reduced extracellular Na ϩ (46 mM, the application of 300 M TBOA blocks conductances because of reverse transport in both CLE1 and the mutant transporter V452C, which reverse the direction at Ϫ48 Ϯ 5 mV (n ϭ 3) and Ϫ52 Ϯ 1 mV (n ϭ 3), respectively, and are ϳ10% of the forward transport conductance activated by 30 M L-glutamate (Fig. 5, A and B) . After MTSET treatment, TBOA block of the reverse transport conductance of CLE1 is unaffected. However, high extracellular K ϩ does not activate any conductance of the MTSET-modified mutant V452C, which can be blocked by TBOA. The conductance activated by reverse transport in the wild-type transporter will also have two components comprised of the coupled movement of glutamate/3Na
ϩ /H ϩ /K ϩ , and the reverse transport-activated chloride conductance (5, 22, 25) . The lack of any conductance blocked by TBOA after MTSET treatment of V452C suggests that both the reverse transport and reverse transport-activated chloride conductance are not activated by high extracellular K ϩ .
To confirm these findings, the reverse transport of 
H]aspartate release (data not shown). The lack of D-[
3 H]aspartate release and the lack of any conductance blocked by TBOA after MTSET treatment of V452C suggest that both the reverse transport and reverse transport-activated chloride conductance are prevented by the MTSET treatment. These results are in contrast to that observed for the effects of MTSET on forward transport where only the coupled transport conductance was inhibited, and these results suggest that the effects of MTSET are asymmetrical with respect to forward and reverse transport activation of the chloride conductance.
DISCUSSION
The observation that glutamate transporters may have a secondary function as glutamate-activated anion channels (3, 26, 27) has raised a number of questions. 1) What is the structural basis for the different functions? 2) How are these two processes coordinated? 3) Is it possible to independently modulate the two processes? In this study, we have described a mutant EAAT-1 transporter V452C that when modified with MTSET selectively blocks glutamate transport while retaining the glutamate-activated uncoupled chloride channel function of the transporter. The EC 50 for glutamate activation of the anion conductance of the MTSET-modified transporter is not significantly different from the EC 50 for glutamate transport and anion conductance activation of the CLE1 or wild-type EAAT-1, which demonstrates that the glutamate recognition site is not significantly altered in the MTSET-modified mutant transporter. Valine 452 is located in a hydrophobic "linker" region that is exposed to the extracellular solution and lies between the reentrant loop that is likely to form the glutamate recognition site (12, 19, 20, 28 -32) and is a putative ␣-helical transmembrane domain containing an arginine residue that may interact with the ␥-carboxyl group of glutamate (33) . The results presented in this study confirm that this linker region is unlikely to be directly involved in glutamate recognition and activation of the anion conductance but do suggest that conformational changes mediated by this region may be required for the translocation of glutamate through the transporter. Fig. 1 in frog Ringer phosphate buffer containing 96 mM NaCl, 96 mM NaBr, 96 mM NaI, or 96 mM NaNO 3 . Current-voltage relationships were measured before (Ⅺ) and after a 5-min incubation (f) with 1 mM MTSET. The data are normalized to the current elicited by 100 M L-glutamate in 96 mM NaCl at Ϫ100 mV and represent the mean currents Ϯ S.E. from five cells.
The activation of the anion conductance of the MTSET-modified V452C mutant transporter requires glutamate binding but clearly does not require active transport, which confirms previous studies (5, 22) suggesting that the binding of glutamate to the transporter without transport is sufficient for activation of the anion conductance. The anion conductance of the MTSET-modified mutant transporter shows some subtle differences compared with the anion conductance that is activated by glutamate binding/transport of the wild-type EAAT-1 and the CLE1 transporter. In addition to the shift in reversal potential of the glutamate-activated conductance before and after MTSET treatment because of the removal of the transport component of the conductance, the amplitude of the anion conductance is significantly greater. These changes in anion conductance amplitude are most apparent with the more permeant anions iodide and nitrate, and in the case of nitrate, the slope conductance measured between 0 and ϩ40 mV was increased 1.9-fold after MTSET treatment. The simplest explanation for these differences in the anion conductance properties is that the MTSET treatment prevents the transporter from undergoing conformational changes required for transport and increases either the open time for the anion channel or the frequency of anion channel opening resulting in a larger anion conductance.
The results presented suggest that MTSET modification of V452C locks the transporter into a conformation that allows glutamate binding and activation of the anion conductance but does not allow translocation of glutamate through the transporter. However, under the conditions that cause the wild-type and CLE1 transporters to function in reverse, MTSET modification of the mutant appears to prevent both reverse transport and reverse transport activation of the anion conductance. This observation can be explained by postulating that MTSET modification of the mutant transporter locks the transporter into a conformation that allows glutamate to bind to an outward facing recognition site but does not allow reorientation of the transporter to bind glutamate from the intracellular surface. Thus, in the absence of glutamate binding to the intracellular recognition site, there is no anion conductance activated and no transporter-associated conductances for TBOA to block (Fig. 5,  B and C) .
The selective manipulation of the transport properties of EAAT-1 without affecting the anion conductance is in contrast to the effects of Zn 2ϩ on the glutamate transporter EAAT-4 in which Zn 2ϩ selectively inhibits the anion conductance without affecting transport (13) . These two studies (34, 35) clearly demonstrate that it is possible to selectively manipulate the two functions of glutamate transporters, which highlights the possibility that the two functions are mediated via separate pore structures. The quaternary structure of the glutamate transporters is unknown, but two studies have suggested that that the transporters associate to form homomultimeric complexes. Electron micrograph studies of EAAT-3 expressed in oocyte membranes suggest that the transporters exist as a pentameric assembly (35) . It was suggested that each transporter "subunit" conducted coupled glutamate transport, whereas the association of the subunits allows the formation of a central chloride channel. If this model is correct, MTSET modification of the mutant transporter may prevent translocation of glutamate by each of the subunits but not alter the conformational changes required for the opening of the central chloride ion channel. Although the structural model proposed by Eskandari et al. (35) can explain how it is possible to independently manipulate the transport and anion channel functions of the transporter, the results presented in this study can also be equally well explained by a common pathway for transport and chloride ion permeation in which the transporter is able to switch between the two modes of operation. Nevertheless, our results do suggest that the transport and chloride Significant differences were demonstrated using the unpaired Student's t test. Similar experiments were also carried out for oocytes expressing CLE1, but no significant differences in the rates of reverse transport with and without MTSET treatment were observed. channel properties are mediated by different conformational states of the transporter, and additional site-directed mutagenesis studies, which identify distinct molecular determinants of the two functions, will be required to distinguish between the single and multiple pore models for glutamate transporter function.
Since the original submission of this paper, a similar study has been published by Seal et al. (36) . This study investigated the effects of MTS reagents on a valine residue 449 to cysteine mutation in EAAT-1 (36) and also showed that MTS reagents abolish glutamate transport but do not affect the anion conductance. If the domain containing these residues is an ␣-helix, the two residues (449 and 452) would be located on the same side of the helix and suggests that this domain may form part of a structure necessary for the transduction of substrate binding into substrate translocation through the transporter.
